Prescribing Information
Kadcyla®(trastuzumab emtansine)
PHESGO®▼ (pertuzumab/trastuzumab)
Polivy®▼ (polatuzumab vedotin)
RoACTEMRA®(tocilizumab) RA/GCA
RoACTEMRA® (tocilizumab) pJIA/sJIA
Tecentriq®▼(atezolizumab) Lung Cancer
Tecentriq®▼(atezolizumab) mTNBC
IV, intravenous; SC, subcutaneous; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; GCA, giant cell arteritis; HCC Hepatocellular carcinoma; pJIA, polyarticular juvenile idiopathic arthritis; sJIA, systemic juvenile idiopathic arthritis; NSCLC, Non-small-cell lung carcinoma; UC, urothelial carcinoma; mTNBC, metastatic triple-negative breast cancer
For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.
M-GB-00002435
Date of preparation: January 2021